The article mentions that Sutro Biopharma has received 2 bullish and 4 somewhat bullish ratings from analysts in the last quarter. This indicates a positive sentiment towards the stock. However, the average 12-month price target has decreased by 14.15% from the previous average, which may indicate a slightly lower growth potential. Overall, the impact on the stock price is likely to be positive in the short term.